Jasiecka-Mikolajczyk A, Socha P
BMC Vet Res. 2024; 20(1):489.
PMID: 39462373
PMC: 11515184.
DOI: 10.1186/s12917-024-04340-0.
Fan J, Ho H, Chiang B
Cell Mol Life Sci. 2024; 81(1):327.
PMID: 39085655
PMC: 11335251.
DOI: 10.1007/s00018-024-05378-x.
Anyalebechi J, Sun Y, Davis C, Wagener M, Liang Z, Burd E
Front Immunol. 2024; 15:1346097.
PMID: 38633258
PMC: 11021695.
DOI: 10.3389/fimmu.2024.1346097.
Liu Z, Baines K, Niessen N, Heer M, Clark D, Bishop G
Front Immunol. 2024; 15:1292158.
PMID: 38333213
PMC: 10850883.
DOI: 10.3389/fimmu.2024.1292158.
Paris-Munoz A, Leon-Triana O, Perez-Martinez A, Barber D
Int J Mol Sci. 2024; 25(1).
PMID: 38203623
PMC: 10778776.
DOI: 10.3390/ijms25010452.
Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy.
Christofi P, Pantazi C, Psatha N, Sakellari I, Yannaki E, Papadopoulou A
Cancers (Basel). 2023; 15(24).
PMID: 38136421
PMC: 10742252.
DOI: 10.3390/cancers15245877.
Elevated Foxp3 double-negative T cells are associated with disease progression during HIV infection.
Zhang L, Wei Y, Wang D, Du J, Wang X, Li B
Front Immunol. 2022; 13:947647.
PMID: 35967422
PMC: 9365964.
DOI: 10.3389/fimmu.2022.947647.
Helios Expression Is Downregulated on CD8 Treg in Two Mouse Models of Lupus During Disease Progression.
Paris-Munoz A, Aizpurua G, Barber D
Front Immunol. 2022; 13:922958.
PMID: 35784310
PMC: 9244697.
DOI: 10.3389/fimmu.2022.922958.
Cytolytic CD4 and CD8 Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease.
Bolivar-Wagers S, Larson J, Jin S, Blazar B
Front Immunol. 2022; 13:864748.
PMID: 35493508
PMC: 9040077.
DOI: 10.3389/fimmu.2022.864748.
The Unfolded Protein Response at the Tumor-Immune Interface.
Zanetti M, Xian S, Dosset M, Carter H
Front Immunol. 2022; 13:823157.
PMID: 35237269
PMC: 8882736.
DOI: 10.3389/fimmu.2022.823157.
Harnessing CD8CD28 Regulatory T Cells as a Tool to Treat Autoimmune Disease.
Ceeraz S, Thompson C, Beatson R, Choy E
Cells. 2021; 10(11).
PMID: 34831195
PMC: 8616472.
DOI: 10.3390/cells10112973.
New Insights on CD8 T Cells in Inflammatory Bowel Disease and Therapeutic Approaches.
Casalegno Garduno R, Dabritz J
Front Immunol. 2021; 12:738762.
PMID: 34707610
PMC: 8542854.
DOI: 10.3389/fimmu.2021.738762.
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.
Wang G, Xu D, Zhang Z, Li X, Shi J, Sun J
NPJ Precis Oncol. 2021; 5(1):56.
PMID: 34158591
PMC: 8219790.
DOI: 10.1038/s41698-021-00200-4.
Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications.
Amini L, Greig J, Schmueck-Henneresse M, Volk H, Bezie S, Reinke P
Front Immunol. 2021; 11:611638.
PMID: 33717052
PMC: 7945682.
DOI: 10.3389/fimmu.2020.611638.
From Discrete to Continuous Modeling of Lymphocyte Development and Plasticity in Chronic Diseases.
Enciso J, Pelayo R, Villarreal C
Front Immunol. 2019; 10:1927.
PMID: 31481957
PMC: 6710364.
DOI: 10.3389/fimmu.2019.01927.
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.
Soundararajan R, Fradette J, Konen J, Moulder S, Zhang X, Gibbons D
Cancers (Basel). 2019; 11(5).
PMID: 31137625
PMC: 6562947.
DOI: 10.3390/cancers11050714.
Identification and functional characterization of CD8+ T regulatory cells in type 1 diabetes patients.
Pellegrino M, Crino A, Rosado M, Fierabracci A
PLoS One. 2019; 14(1):e0210839.
PMID: 30650147
PMC: 6334945.
DOI: 10.1371/journal.pone.0210839.
Cord Blood CD8 T Cells Have a Natural Propensity to Express IL-4 in a Fatty Acid Metabolism and Caspase Activation-Dependent Manner.
Zhang Y, Maksimovic J, Huang B, De Souza D, Naselli G, Chen H
Front Immunol. 2018; 9:879.
PMID: 29922282
PMC: 5996926.
DOI: 10.3389/fimmu.2018.00879.
Bim regulates the survival and suppressive capability of CD8 FOXP3 regulatory T cells during murine GVHD.
Agle K, Vincent B, Piper C, Belle L, Zhou V, Shlomchik W
Blood. 2018; 132(4):435-447.
PMID: 29769260
PMC: 6071561.
DOI: 10.1182/blood-2017-09-807156.
Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes.
Walsh E, Keane M, Wink D, Callagy G, Glynn S
Crit Rev Oncog. 2018; 21(5-6):333-351.
PMID: 29431082
PMC: 6353632.
DOI: 10.1615/CritRevOncog.2017021307.